Both Acceleron Pharma Inc. (NASDAQ:XLRN) and Mustang Bio Inc. (NASDAQ:MBIO) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acceleron Pharma Inc.	13.99M	174.97	118.87M	-2.45	0.00
Mustang Bio Inc.	N/A	0.00	30.66M	-1.30	0.00

Table 1 highlights Acceleron Pharma Inc. and Mustang Bio Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Acceleron Pharma Inc. (NASDAQ:XLRN) and Mustang Bio Inc. (NASDAQ:MBIO)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acceleron Pharma Inc.	-849.68%	-36.6%	-34.6%
Mustang Bio Inc.	0.00%	-65.1%	-60%

Liquidity

Acceleron Pharma Inc.’s Current Ratio and Quick Ratio are 16.2 and 16.2 respectively. The Current Ratio and Quick Ratio of its competitor Mustang Bio Inc. are 10.3 and 10.3 respectively. Acceleron Pharma Inc. therefore has a better chance of paying off short and long-term obligations compared to Mustang Bio Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Acceleron Pharma Inc. and Mustang Bio Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Acceleron Pharma Inc.	0	0	2	3.00
Mustang Bio Inc.	0	0	0	0.00

Acceleron Pharma Inc. has a 53.08% upside potential and an average target price of $72.5.

Insider & Institutional Ownership

The shares of both Acceleron Pharma Inc. and Mustang Bio Inc. are owned by institutional investors at 87.4% and 9.6% respectively. 14.2% are Acceleron Pharma Inc.’s share held by insiders. On the other hand, insiders held about 1.1% of Mustang Bio Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Acceleron Pharma Inc.	9.34%	9.06%	-13.57%	-13.2%	13.86%	6.18%
Mustang Bio Inc.	-13.73%	1.34%	-2.08%	-45.36%	-64.63%	28.23%

For the past year Acceleron Pharma Inc. has weaker performance than Mustang Bio Inc.

Summary

Acceleron Pharma Inc. beats Mustang Bio Inc. on 6 of the 10 factors.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.